<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Han K</submitter><funding>Intramural NIH HHS</funding><funding>Medical Research Council</funding><funding>NHLBI NIH HHS</funding><funding>NIH HHS</funding><pagination>101157</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10518596</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>4(9)</volume><pubmed_abstract>To evaluate whether nicotinamide adenine dinucleotide-positive (NAD&lt;sup>+&lt;/sup>) boosting modulates adaptive immunity, primary CD4&lt;sup>+&lt;/sup> T cells from healthy control and psoriasis subjects were exposed to vehicle or nicotinamide riboside (NR) supplementation. NR blunts interferon γ (IFNγ) and interleukin (IL)-17 secretion with greater effects on T helper (Th) 17 polarization. RNA sequencing (RNA-seq) analysis implicates NR blunting of sequestosome 1 (sqstm1/p62)-coupled oxidative stress. NR administration increases sqstm1 and reduces reactive oxygen species (ROS) levels. Furthermore, NR activates nuclear factor erythroid 2-related factor 2 (Nrf2), and genetic knockdown of nrf2 and the Nrf2-dependent gene, sqstm1, diminishes NR amelioratory effects. Metabolomics analysis identifies th</pubmed_abstract><journal>Cell reports. Medicine</journal><pubmed_title>Boosting NAD preferentially blunts Th17 inflammation via arginine biosynthesis and redox control in healthy and psoriasis subjects.</pubmed_title><pmcid>PMC10518596</pmcid><funding_grant_id>ZIA HL005102</funding_grant_id><funding_grant_id>S10 OD021562</funding_grant_id><funding_grant_id>MR/P011705/2</funding_grant_id><funding_grant_id>R01 HL129510</funding_grant_id><funding_grant_id>MR/P011705/1</funding_grant_id><funding_grant_id>MR/X012700/1</funding_grant_id><pubmed_authors>Wu J</pubmed_authors><pubmed_authors>Goss-Holmes H</pubmed_authors><pubmed_authors>Han K</pubmed_authors><pubmed_authors>Sack MN</pubmed_authors><pubmed_authors>Sharma R</pubmed_authors><pubmed_authors>Griffin JL</pubmed_authors><pubmed_authors>Hassanzadeh S</pubmed_authors><pubmed_authors>Huffstutler RD</pubmed_authors><pubmed_authors>Singh K</pubmed_authors><pubmed_authors>Teague HL</pubmed_authors><pubmed_authors>Mehta NN</pubmed_authors><pubmed_authors>Traba J</pubmed_authors><pubmed_authors>Tian R</pubmed_authors><pubmed_authors>Meadows AM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Boosting NAD preferentially blunts Th17 inflammation via arginine biosynthesis and redox control in healthy and psoriasis subjects.</name><description>To evaluate whether nicotinamide adenine dinucleotide-positive (NAD&lt;sup>+&lt;/sup>) boosting modulates adaptive immunity, primary CD4&lt;sup>+&lt;/sup> T cells from healthy control and psoriasis subjects were exposed to vehicle or nicotinamide riboside (NR) supplementation. NR blunts interferon γ (IFNγ) and interleukin (IL)-17 secretion with greater effects on T helper (Th) 17 polarization. RNA sequencing (RNA-seq) analysis implicates NR blunting of sequestosome 1 (sqstm1/p62)-coupled oxidative stress. NR administration increases sqstm1 and reduces reactive oxygen species (ROS) levels. Furthermore, NR activates nuclear factor erythroid 2-related factor 2 (Nrf2), and genetic knockdown of nrf2 and the Nrf2-dependent gene, sqstm1, diminishes NR amelioratory effects. Metabolomics analysis identifies th</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2026-05-28T12:35:21.124Z</modification><creation>2025-04-06T18:54:39.107Z</creation></dates><accession>S-EPMC10518596</accession><cross_references><pubmed>37586364</pubmed><doi>10.1016/j.xcrm.2023.101157</doi></cross_references></HashMap>